Merck won't change endpoint in new Vytorin trial

Merck resisted a steering committee's recommendation to change the primary endpoint in a new clinical trial of its cholesterol drug Vytorin in chronic kidney patients, three years after an endpoint change in the Enhance trial of that drug drew a firestorm of criticism. Report